Count Me In is aiming to sign up more than 100,000 patients across all major cancer types, as well as rare cancers, over the next several years.
The investment bank said it is encouraged by the company's strong pipeline and position among its competitors but sees further upside for its stock.
The company said it will use the proceeds to develop new liquid biopsy tests to predict drug response in cancer patients.
The companies will combine GenomOncology's GO Immuno-Oncology Workbench analysis software with Fluidigm's Advanta IO Gene Expression Assay.
The companies will incorporate PerkinElmer's LabChip GX Touch nucleic acid analyzer in the upfront workflow of Agena's MassArray system.
A study found that cis-regulatory variation modifies the penetrance of coding variants, and that variants' regulatory haplotype configuration affects disease risk.
The China-based company said that it now has 11 products that have been CE marked, and has applied for additional CE certification for other tests.
IBM's supercomputing platform will continue to provide AI support to advanced cancer patients at VA medical centers for at least another year.
The partners will use NanoString's PanCancer panel in NCI-sponsored trials to characterize immune activity and develop potentially predictive gene signatures.
The technology behind Mammoth's platform bears a striking resemblance to the CRISPR-based SHERLOCK platform developed by researchers at the Broad Institute.
Researchers have sequenced the genome of the depth-dwelling giant squid.
Prosecutors have charged a former Drexel University professor with theft for allegedly spending federal grant money on adult entertainment and other unrelated expenses, according to the Philadelphia Inquirer.
Chris Collins, a former US representative, has been sentenced to more than two years in prison in an insider trading case involving an Australian biotechnology firm, the New York Times reports.
In PNAS this week: Trypanosoma brucei transcripts, estimate of people at risk of inherited retinal disease, and more.